These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 39170618)
41. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer. Marcus A; Eshhar Z Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086 [TBL] [Abstract][Full Text] [Related]
42. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia? Zhang M; Huang H Front Immunol; 2020; 11():611710. PubMed ID: 33384696 [TBL] [Abstract][Full Text] [Related]
43. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial. Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958 [TBL] [Abstract][Full Text] [Related]
46. Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation. Ueha S; Yokochi S; Ishiwata Y; Kosugi-Kanaya M; Shono Y; Shibayama S; Ito S; Matsushima K Cancer Sci; 2017 Oct; 108(10):1967-1973. PubMed ID: 28787768 [TBL] [Abstract][Full Text] [Related]
47. Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention. Li YR; Dunn ZS; Garcia G; Carmona C; Zhou Y; Lee D; Yu J; Huang J; Kim JT; Arumugaswami V; Wang P; Yang L Stem Cell Res Ther; 2022 Mar; 13(1):112. PubMed ID: 35313965 [TBL] [Abstract][Full Text] [Related]
48. [Advances in Allogeneic Chimeric Antigen Receptor T Cells]. Zhao Q; Li F Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Dec; 45(6):967-972. PubMed ID: 38173109 [TBL] [Abstract][Full Text] [Related]
49. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
50. Impaired thymic iNKT cell differentiation at early precursor stage in murine haploidentical bone marrow transplantation with GvHD. Zhao W; Wang Y; Zhang X; Hao J; Zhang K; Huang X; Chang Y; Wu H; Jin R; Ge Q Front Immunol; 2023; 14():1203614. PubMed ID: 37600815 [TBL] [Abstract][Full Text] [Related]
51. Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study. Barkholt L; Alici E; Conrad R; Sutlu T; Gilljam M; Stellan B; Christensson B; Guven H; Björkström NK; Söderdahl G; Cederlund K; Kimby E; Aschan J; Ringdén O; Ljunggren HG; Dilber MS Immunotherapy; 2009 Sep; 1(5):753-64. PubMed ID: 20636021 [TBL] [Abstract][Full Text] [Related]
52. Target tumor microenvironment by innate T cells. Li YR; Wilson M; Yang L Front Immunol; 2022; 13():999549. PubMed ID: 36275727 [TBL] [Abstract][Full Text] [Related]
53. iNKT cells and hematopoietic stem cell transplantation: Two-phase activation of iNKT cells may improve outcome. Fereidouni M; Derakhshani A; Exley MA Clin Immunol; 2019 Oct; 207():43-48. PubMed ID: 31128279 [TBL] [Abstract][Full Text] [Related]
54. Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials. Smirnov S; Petukhov A; Levchuk K; Kulemzin S; Staliarova A; Lepik K; Shuvalov O; Zaritskey A; Daks A; Fedorova O Front Immunol; 2021; 12():780145. PubMed ID: 34975869 [TBL] [Abstract][Full Text] [Related]
55. Extracorporeal photopheresis as a promising strategy for the treatment of graft-versus-host disease after CAR T-cell therapy. Han H; Wang L; Ding Y; Neuber B; Hückelhoven-Krauss A; Lin M; Yao H; Chen Q; Sauer T; Schubert ML; Guo Z; Müller-Tidow C; Schmitt M; Schmitt A Blood Adv; 2024 Jun; 8(11):2675-2690. PubMed ID: 38359409 [TBL] [Abstract][Full Text] [Related]
56. Host-residual invariant NK T cells attenuate graft-versus-host immunity. Haraguchi K; Takahashi T; Matsumoto A; Asai T; Kanda Y; Kurokawa M; Ogawa S; Oda H; Taniguchi M; Hirai H; Chiba S J Immunol; 2005 Jul; 175(2):1320-8. PubMed ID: 16002737 [TBL] [Abstract][Full Text] [Related]
57. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256 [TBL] [Abstract][Full Text] [Related]
58. Human Herpes Virus-6 (HHV-6) Reactivation after Hematopoietic Cell Transplant and Chimeric Antigen Receptor (CAR)- T Cell Therapy: A Shifting Landscape. Kampouri E; Handley G; Hill JA Viruses; 2024 Mar; 16(4):. PubMed ID: 38675841 [TBL] [Abstract][Full Text] [Related]
59. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia. Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P Front Immunol; 2021; 12():605766. PubMed ID: 34025637 [TBL] [Abstract][Full Text] [Related]
60. Paving the Way Towards Universal Chimeric Antigen Receptor Therapy in Cancer Treatment: Current Landscape and Progress. Zhang Y; Li P; Fang H; Wang G; Zeng X Front Immunol; 2020; 11():604915. PubMed ID: 33362790 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]